Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Respiratory Syncytial Virus Infections | 96 | 2025 | 345 | 14.820 |
Why?
|
Respiratory Syncytial Virus, Human | 59 | 2025 | 207 | 12.770 |
Why?
|
Bronchiolitis | 53 | 2022 | 122 | 8.180 |
Why?
|
Respiratory Syncytial Virus Vaccines | 24 | 2025 | 70 | 5.820 |
Why?
|
Influenza, Human | 45 | 2024 | 662 | 4.720 |
Why?
|
Antibodies, Viral | 54 | 2025 | 1150 | 4.370 |
Why?
|
Respiratory Syncytial Viruses | 35 | 2025 | 147 | 4.280 |
Why?
|
Respiratory Tract Infections | 26 | 2024 | 274 | 4.090 |
Why?
|
Viral Fusion Proteins | 18 | 2023 | 76 | 3.100 |
Why?
|
Influenza Vaccines | 30 | 2023 | 480 | 3.020 |
Why?
|
Picornaviridae Infections | 17 | 2024 | 48 | 2.790 |
Why?
|
Antiviral Agents | 22 | 2025 | 767 | 2.560 |
Why?
|
Antibodies, Neutralizing | 23 | 2023 | 469 | 2.500 |
Why?
|
Viral Load | 17 | 2025 | 389 | 2.410 |
Why?
|
Bronchiolitis, Viral | 14 | 2021 | 30 | 2.250 |
Why?
|
Nasopharynx | 22 | 2022 | 80 | 2.170 |
Why?
|
Infant | 138 | 2025 | 12610 | 2.160 |
Why?
|
Rhinovirus | 20 | 2022 | 59 | 2.150 |
Why?
|
Viruses | 9 | 2024 | 122 | 2.130 |
Why?
|
Hospitalization | 41 | 2024 | 1784 | 2.080 |
Why?
|
Virus Diseases | 10 | 2022 | 281 | 1.930 |
Why?
|
Enterovirus | 3 | 2024 | 52 | 1.540 |
Why?
|
Viral Vaccines | 11 | 2015 | 337 | 1.410 |
Why?
|
Humans | 234 | 2025 | 125110 | 1.380 |
Why?
|
Immunity, Humoral | 2 | 2021 | 71 | 1.370 |
Why?
|
Enterovirus Infections | 2 | 2024 | 49 | 1.370 |
Why?
|
Metapneumovirus | 8 | 2022 | 50 | 1.340 |
Why?
|
Respiratory Sounds | 13 | 2021 | 70 | 1.290 |
Why?
|
Prospective Studies | 56 | 2025 | 6123 | 1.210 |
Why?
|
Transplant Recipients | 3 | 2021 | 218 | 1.180 |
Why?
|
Hematopoietic Stem Cell Transplantation | 6 | 2021 | 1097 | 1.150 |
Why?
|
Female | 138 | 2025 | 66704 | 1.090 |
Why?
|
Dibenzothiepins | 3 | 2023 | 3 | 1.080 |
Why?
|
Child, Preschool | 78 | 2025 | 14152 | 1.020 |
Why?
|
Immunoglobulin G | 10 | 2021 | 780 | 0.990 |
Why?
|
Male | 126 | 2025 | 61443 | 0.990 |
Why?
|
Bodily Secretions | 2 | 2016 | 7 | 0.980 |
Why?
|
Nanoparticles | 8 | 2025 | 230 | 0.960 |
Why?
|
Palivizumab | 6 | 2021 | 47 | 0.950 |
Why?
|
Neutralization Tests | 14 | 2016 | 236 | 0.950 |
Why?
|
Infant, Newborn | 45 | 2025 | 8275 | 0.940 |
Why?
|
Microbiota | 11 | 2022 | 387 | 0.930 |
Why?
|
Influenza A Virus, H1N1 Subtype | 9 | 2019 | 178 | 0.920 |
Why?
|
Vaccines, Attenuated | 15 | 2019 | 175 | 0.920 |
Why?
|
Orthomyxoviridae | 8 | 2023 | 51 | 0.910 |
Why?
|
Triazines | 3 | 2023 | 30 | 0.910 |
Why?
|
Influenza A Virus, H3N2 Subtype | 6 | 2023 | 115 | 0.910 |
Why?
|
RNA, Viral | 10 | 2024 | 537 | 0.900 |
Why?
|
Immunoglobulin A | 4 | 2021 | 207 | 0.890 |
Why?
|
L-Lactate Dehydrogenase | 3 | 2014 | 61 | 0.870 |
Why?
|
Leukocytes, Mononuclear | 3 | 2022 | 325 | 0.860 |
Why?
|
Pyridones | 3 | 2023 | 118 | 0.850 |
Why?
|
Morpholines | 2 | 2020 | 59 | 0.840 |
Why?
|
Adult | 50 | 2025 | 29459 | 0.830 |
Why?
|
Cystic Fibrosis | 7 | 2007 | 259 | 0.820 |
Why?
|
Adenoviridae | 13 | 2022 | 605 | 0.800 |
Why?
|
Recombinant Fusion Proteins | 4 | 2016 | 771 | 0.780 |
Why?
|
Immunity, Mucosal | 2 | 2025 | 87 | 0.770 |
Why?
|
Cytokines | 8 | 2024 | 1293 | 0.760 |
Why?
|
Seasons | 10 | 2024 | 312 | 0.760 |
Why?
|
Asthma | 11 | 2021 | 756 | 0.750 |
Why?
|
Viral Structural Proteins | 1 | 2021 | 48 | 0.730 |
Why?
|
Virus Replication | 14 | 2025 | 607 | 0.710 |
Why?
|
Child | 63 | 2024 | 24610 | 0.700 |
Why?
|
Antigens, Viral | 10 | 2024 | 438 | 0.690 |
Why?
|
Disease Outbreaks | 7 | 2023 | 320 | 0.680 |
Why?
|
Vaccination | 17 | 2023 | 961 | 0.660 |
Why?
|
Nasal Mucosa | 5 | 2024 | 66 | 0.630 |
Why?
|
Influenza A Virus, H5N1 Subtype | 2 | 2024 | 61 | 0.630 |
Why?
|
Bacterial Infections | 2 | 2019 | 304 | 0.620 |
Why?
|
Community-Acquired Infections | 3 | 2013 | 241 | 0.620 |
Why?
|
Bordetella pertussis | 2 | 2016 | 16 | 0.610 |
Why?
|
Influenza B virus | 7 | 2015 | 87 | 0.590 |
Why?
|
Immunity, Maternally-Acquired | 2 | 2014 | 35 | 0.590 |
Why?
|
Cohort Studies | 24 | 2024 | 4821 | 0.590 |
Why?
|
Pregnancy Complications, Infectious | 4 | 2019 | 455 | 0.580 |
Why?
|
Respiratory Insufficiency | 1 | 2020 | 226 | 0.580 |
Why?
|
Adolescent | 42 | 2024 | 19414 | 0.580 |
Why?
|
Real-Time Polymerase Chain Reaction | 9 | 2021 | 508 | 0.570 |
Why?
|
Genes, Viral | 2 | 2017 | 185 | 0.560 |
Why?
|
Genotype | 10 | 2021 | 2569 | 0.560 |
Why?
|
Adenoviridae Infections | 4 | 2008 | 71 | 0.550 |
Why?
|
Virus Shedding | 5 | 2021 | 81 | 0.550 |
Why?
|
Molecular Diagnostic Techniques | 5 | 2022 | 152 | 0.550 |
Why?
|
Texas | 14 | 2021 | 3571 | 0.550 |
Why?
|
Paramyxoviridae Infections | 6 | 2022 | 46 | 0.550 |
Why?
|
Length of Stay | 11 | 2017 | 1306 | 0.540 |
Why?
|
Adenovirus Infections, Human | 5 | 2003 | 50 | 0.530 |
Why?
|
Pneumonia, Viral | 4 | 2020 | 377 | 0.530 |
Why?
|
Adjuvants, Immunologic | 9 | 2025 | 381 | 0.520 |
Why?
|
Sigmodontinae | 13 | 2025 | 44 | 0.520 |
Why?
|
Severity of Illness Index | 23 | 2022 | 2906 | 0.520 |
Why?
|
Viral Proteins | 6 | 2016 | 347 | 0.510 |
Why?
|
Immunization Programs | 4 | 2008 | 63 | 0.500 |
Why?
|
Adenoviruses, Human | 4 | 2003 | 81 | 0.500 |
Why?
|
Young Adult | 21 | 2021 | 9056 | 0.500 |
Why?
|
Genome, Viral | 4 | 2024 | 165 | 0.490 |
Why?
|
Influenza A virus | 11 | 2015 | 138 | 0.480 |
Why?
|
Lung | 13 | 2025 | 1492 | 0.480 |
Why?
|
Nasal Lavage Fluid | 3 | 2016 | 14 | 0.470 |
Why?
|
Common Cold | 4 | 2019 | 22 | 0.470 |
Why?
|
Vaccines, Synthetic | 8 | 2020 | 316 | 0.470 |
Why?
|
Whooping Cough | 1 | 2015 | 60 | 0.460 |
Why?
|
Infant, Premature, Diseases | 3 | 2010 | 245 | 0.440 |
Why?
|
Maternal-Fetal Exchange | 1 | 2014 | 81 | 0.440 |
Why?
|
Administration, Intranasal | 13 | 2025 | 132 | 0.440 |
Why?
|
Antibody Formation | 6 | 2021 | 265 | 0.430 |
Why?
|
Caspases | 1 | 2014 | 163 | 0.430 |
Why?
|
Antibodies, Monoclonal, Humanized | 3 | 2025 | 509 | 0.410 |
Why?
|
Coinfection | 5 | 2024 | 172 | 0.410 |
Why?
|
Continuous Positive Airway Pressure | 2 | 2015 | 53 | 0.410 |
Why?
|
HN Protein | 3 | 1998 | 18 | 0.390 |
Why?
|
Metabolome | 5 | 2021 | 293 | 0.390 |
Why?
|
Middle Aged | 26 | 2025 | 26676 | 0.390 |
Why?
|
Infant, Premature | 3 | 2020 | 833 | 0.390 |
Why?
|
Coronavirus | 3 | 2022 | 25 | 0.390 |
Why?
|
Vaccines, Inactivated | 6 | 2019 | 144 | 0.390 |
Why?
|
Pregnancy | 14 | 2022 | 7221 | 0.370 |
Why?
|
Antimicrobial Cationic Peptides | 3 | 2017 | 38 | 0.370 |
Why?
|
Phenotype | 1 | 2021 | 4270 | 0.370 |
Why?
|
Oseltamivir | 2 | 2022 | 16 | 0.370 |
Why?
|
United States | 23 | 2025 | 10884 | 0.350 |
Why?
|
Immunity, Herd | 3 | 2010 | 12 | 0.340 |
Why?
|
Spike Glycoprotein, Coronavirus | 3 | 2021 | 187 | 0.340 |
Why?
|
Drug Resistance, Viral | 5 | 2022 | 47 | 0.340 |
Why?
|
Lung Diseases | 5 | 2016 | 385 | 0.330 |
Why?
|
Nasal Cavity | 4 | 2018 | 50 | 0.320 |
Why?
|
Cell Line | 8 | 2023 | 2756 | 0.320 |
Why?
|
Cost of Illness | 2 | 2025 | 251 | 0.320 |
Why?
|
Respiratory Tract Diseases | 5 | 2022 | 75 | 0.320 |
Why?
|
Intubation, Intratracheal | 2 | 2012 | 287 | 0.310 |
Why?
|
Eczema | 2 | 2021 | 29 | 0.310 |
Why?
|
Cross Infection | 4 | 2021 | 313 | 0.310 |
Why?
|
Double-Blind Method | 10 | 2020 | 1605 | 0.310 |
Why?
|
Aged | 20 | 2021 | 19656 | 0.310 |
Why?
|
Social Change | 1 | 2008 | 15 | 0.310 |
Why?
|
Acute Disease | 8 | 2024 | 1095 | 0.300 |
Why?
|
Single-Domain Antibodies | 2 | 2020 | 8 | 0.300 |
Why?
|
Respirovirus Infections | 6 | 2017 | 19 | 0.300 |
Why?
|
RNA, Ribosomal, 16S | 3 | 2019 | 362 | 0.290 |
Why?
|
Vaccines, Virus-Like Particle | 2 | 2019 | 33 | 0.290 |
Why?
|
Finland | 8 | 2021 | 42 | 0.290 |
Why?
|
Sequence Analysis, DNA | 5 | 2024 | 1762 | 0.290 |
Why?
|
Pandemics | 6 | 2023 | 1112 | 0.280 |
Why?
|
Ribavirin | 4 | 2003 | 85 | 0.280 |
Why?
|
Longitudinal Studies | 6 | 2025 | 1319 | 0.280 |
Why?
|
Animals | 36 | 2025 | 34304 | 0.280 |
Why?
|
Intensive Care Units | 5 | 2020 | 493 | 0.280 |
Why?
|
Cross-Sectional Studies | 6 | 2022 | 3402 | 0.280 |
Why?
|
Infant, Low Birth Weight | 3 | 2020 | 167 | 0.270 |
Why?
|
Moraxella | 4 | 2019 | 14 | 0.270 |
Why?
|
Liposomes | 2 | 2025 | 188 | 0.270 |
Why?
|
Genetic Vectors | 8 | 2014 | 940 | 0.270 |
Why?
|
Haemophilus | 4 | 2019 | 13 | 0.270 |
Why?
|
Genetic Variation | 6 | 2021 | 1505 | 0.260 |
Why?
|
Bronchodilator Agents | 4 | 2017 | 151 | 0.260 |
Why?
|
Host-Pathogen Interactions | 3 | 2025 | 253 | 0.260 |
Why?
|
Viral Envelope Proteins | 4 | 2020 | 152 | 0.250 |
Why?
|
Protein Conformation | 2 | 2018 | 837 | 0.240 |
Why?
|
Respiratory System | 3 | 2021 | 97 | 0.240 |
Why?
|
Drug Discovery | 2 | 2018 | 171 | 0.240 |
Why?
|
Streptococcus | 3 | 2019 | 60 | 0.230 |
Why?
|
Fever | 3 | 2024 | 297 | 0.230 |
Why?
|
Immunoglobulins, Intravenous | 2 | 2003 | 145 | 0.230 |
Why?
|
N-Acetylneuraminic Acid | 1 | 2004 | 27 | 0.230 |
Why?
|
Mice, Inbred BALB C | 9 | 2025 | 1000 | 0.220 |
Why?
|
Organoids | 2 | 2024 | 280 | 0.220 |
Why?
|
Child Welfare | 1 | 2004 | 65 | 0.220 |
Why?
|
Critical Care | 5 | 2017 | 656 | 0.220 |
Why?
|
Pregnancy Complications | 2 | 2022 | 515 | 0.220 |
Why?
|
Polymerase Chain Reaction | 5 | 2016 | 1592 | 0.220 |
Why?
|
Immunity, Innate | 3 | 2024 | 372 | 0.220 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 5 | 2020 | 825 | 0.220 |
Why?
|
Immunocompromised Host | 5 | 2017 | 293 | 0.220 |
Why?
|
Placebos | 4 | 2019 | 237 | 0.210 |
Why?
|
Acetamides | 1 | 2024 | 47 | 0.210 |
Why?
|
Pharynx | 3 | 2016 | 66 | 0.210 |
Why?
|
Incidence | 9 | 2021 | 3131 | 0.210 |
Why?
|
Staphylococcus | 3 | 2018 | 68 | 0.210 |
Why?
|
Poliovirus | 1 | 2023 | 47 | 0.210 |
Why?
|
Sulfonamides | 2 | 2015 | 270 | 0.210 |
Why?
|
Administration, Oral | 3 | 2020 | 683 | 0.210 |
Why?
|
Thiepins | 1 | 2023 | 1 | 0.210 |
Why?
|
Aged, 80 and over | 8 | 2021 | 6537 | 0.200 |
Why?
|
Epidemiological Monitoring | 2 | 2024 | 58 | 0.200 |
Why?
|
Respiratory Mucosa | 2 | 2020 | 91 | 0.200 |
Why?
|
Pyrazoles | 2 | 2015 | 306 | 0.200 |
Why?
|
Bacteria | 2 | 2019 | 477 | 0.200 |
Why?
|
Antibodies, Monoclonal | 6 | 2018 | 1026 | 0.200 |
Why?
|
Biomarkers | 5 | 2019 | 3105 | 0.200 |
Why?
|
Amino Acid Sequence | 3 | 2017 | 2717 | 0.190 |
Why?
|
Prenatal Exposure Delayed Effects | 2 | 2015 | 229 | 0.190 |
Why?
|
Interleukin-4 | 2 | 2001 | 140 | 0.190 |
Why?
|
Disease Models, Animal | 6 | 2021 | 4408 | 0.180 |
Why?
|
Formaldehyde | 2 | 1993 | 37 | 0.180 |
Why?
|
Drug Administration Schedule | 4 | 2020 | 728 | 0.180 |
Why?
|
Age Factors | 9 | 2019 | 2815 | 0.180 |
Why?
|
Phylogeny | 5 | 2024 | 686 | 0.180 |
Why?
|
Interferon-gamma | 2 | 2017 | 505 | 0.180 |
Why?
|
Chemokine CCL5 | 2 | 2018 | 53 | 0.180 |
Why?
|
Viremia | 3 | 2014 | 129 | 0.180 |
Why?
|
Lipids | 1 | 2004 | 519 | 0.180 |
Why?
|
Kava | 1 | 2020 | 7 | 0.180 |
Why?
|
CD8-Positive T-Lymphocytes | 3 | 2008 | 396 | 0.170 |
Why?
|
Drug Compounding | 1 | 2020 | 36 | 0.170 |
Why?
|
Rats | 9 | 2018 | 3728 | 0.170 |
Why?
|
Drug Evaluation, Preclinical | 2 | 2018 | 155 | 0.170 |
Why?
|
Recombinant Proteins | 3 | 2021 | 1400 | 0.170 |
Why?
|
Recurrence | 6 | 2021 | 1390 | 0.170 |
Why?
|
Endonucleases | 1 | 2020 | 55 | 0.170 |
Why?
|
Smoking | 3 | 2015 | 1049 | 0.170 |
Why?
|
Infant, Newborn, Diseases | 2 | 2020 | 171 | 0.170 |
Why?
|
Antigenic Variation | 2 | 2017 | 39 | 0.170 |
Why?
|
Population Surveillance | 2 | 2017 | 390 | 0.170 |
Why?
|
Immunity, Cellular | 2 | 2017 | 205 | 0.160 |
Why?
|
Chronic Disease | 3 | 2016 | 1187 | 0.160 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 73 | 0.160 |
Why?
|
Coxsackievirus Infections | 1 | 2019 | 10 | 0.160 |
Why?
|
T-Lymphocytes, Cytotoxic | 5 | 2004 | 505 | 0.160 |
Why?
|
T-Lymphocytes | 4 | 2021 | 1720 | 0.160 |
Why?
|
Vero Cells | 4 | 2020 | 109 | 0.160 |
Why?
|
Peptides | 2 | 2021 | 812 | 0.160 |
Why?
|
Treatment Outcome | 17 | 2020 | 12272 | 0.160 |
Why?
|
Chile | 3 | 2017 | 22 | 0.160 |
Why?
|
HEK293 Cells | 1 | 2021 | 738 | 0.160 |
Why?
|
Dose-Response Relationship, Immunologic | 2 | 2017 | 108 | 0.160 |
Why?
|
Risk Assessment | 5 | 2020 | 3424 | 0.160 |
Why?
|
Cities | 3 | 2024 | 47 | 0.150 |
Why?
|
Respiratory Hypersensitivity | 1 | 2019 | 52 | 0.150 |
Why?
|
Blood Proteins | 1 | 2019 | 124 | 0.150 |
Why?
|
Immunoglobulin E | 2 | 2019 | 162 | 0.150 |
Why?
|
Kinetics | 1 | 2021 | 1330 | 0.150 |
Why?
|
Drug Carriers | 2 | 2014 | 99 | 0.150 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 5 | 2013 | 1294 | 0.150 |
Why?
|
Risk Factors | 11 | 2021 | 10278 | 0.150 |
Why?
|
Japan | 3 | 2023 | 135 | 0.150 |
Why?
|
Respiration | 1 | 1999 | 122 | 0.150 |
Why?
|
Global Health | 2 | 2020 | 570 | 0.150 |
Why?
|
Laboratories | 1 | 2019 | 81 | 0.150 |
Why?
|
Allografts | 1 | 2019 | 176 | 0.150 |
Why?
|
Retrospective Studies | 9 | 2020 | 16339 | 0.150 |
Why?
|
Virus Internalization | 2 | 2015 | 55 | 0.150 |
Why?
|
Hand, Foot and Mouth Disease | 1 | 2017 | 3 | 0.150 |
Why?
|
Vietnam | 1 | 2017 | 48 | 0.140 |
Why?
|
Respiration, Artificial | 3 | 2015 | 473 | 0.140 |
Why?
|
Anti-Retroviral Agents | 1 | 2019 | 141 | 0.140 |
Why?
|
Aluminum Compounds | 2 | 2018 | 17 | 0.140 |
Why?
|
Maternal Exposure | 1 | 2019 | 149 | 0.140 |
Why?
|
Parainfluenza Virus 3, Human | 1 | 2017 | 12 | 0.140 |
Why?
|
Seroepidemiologic Studies | 2 | 2021 | 122 | 0.140 |
Why?
|
Machine Learning | 1 | 2020 | 250 | 0.140 |
Why?
|
Logistic Models | 4 | 2015 | 1800 | 0.140 |
Why?
|
HIV Infections | 2 | 2019 | 1896 | 0.140 |
Why?
|
Injections, Intramuscular | 3 | 2020 | 194 | 0.140 |
Why?
|
Albuterol | 1 | 2017 | 52 | 0.140 |
Why?
|
Phosphates | 2 | 2018 | 115 | 0.140 |
Why?
|
Health Care Costs | 1 | 2020 | 371 | 0.130 |
Why?
|
Risk | 3 | 2019 | 759 | 0.130 |
Why?
|
Time Factors | 6 | 2020 | 6302 | 0.130 |
Why?
|
Immunization Schedule | 4 | 2020 | 102 | 0.130 |
Why?
|
Multivariate Analysis | 4 | 2015 | 1425 | 0.130 |
Why?
|
Macrolides | 1 | 2016 | 29 | 0.130 |
Why?
|
Interferons | 2 | 2017 | 126 | 0.130 |
Why?
|
Azithromycin | 1 | 2016 | 43 | 0.130 |
Why?
|
Epinephrine | 1 | 2017 | 177 | 0.130 |
Why?
|
Cystitis | 1 | 1996 | 42 | 0.130 |
Why?
|
Proportional Hazards Models | 3 | 2021 | 1361 | 0.130 |
Why?
|
Food Hypersensitivity | 1 | 2019 | 154 | 0.130 |
Why?
|
Administration, Inhalation | 7 | 2020 | 180 | 0.120 |
Why?
|
Amino Acid Substitution | 1 | 2017 | 398 | 0.120 |
Why?
|
Immunotherapy, Adoptive | 2 | 2017 | 832 | 0.120 |
Why?
|
Feces | 2 | 2016 | 727 | 0.120 |
Why?
|
NF-kappa B | 1 | 2018 | 462 | 0.120 |
Why?
|
Mycoplasma pneumoniae | 1 | 2015 | 12 | 0.120 |
Why?
|
Prevalence | 4 | 2015 | 2458 | 0.120 |
Why?
|
Pregnancy Outcome | 1 | 2018 | 596 | 0.120 |
Why?
|
Retroviridae Proteins, Oncogenic | 1 | 2014 | 12 | 0.120 |
Why?
|
Tobacco Smoke Pollution | 1 | 2015 | 77 | 0.120 |
Why?
|
Nonprescription Drugs | 1 | 2015 | 47 | 0.120 |
Why?
|
Coronavirus Infections | 1 | 2020 | 361 | 0.120 |
Why?
|
Outpatients | 2 | 2021 | 250 | 0.120 |
Why?
|
Molecular Typing | 3 | 2021 | 34 | 0.110 |
Why?
|
Prognosis | 5 | 2015 | 4683 | 0.110 |
Why?
|
Anti-Asthmatic Agents | 1 | 2016 | 112 | 0.110 |
Why?
|
Antibiotic Prophylaxis | 1 | 2015 | 116 | 0.110 |
Why?
|
Hyponatremia | 1 | 2015 | 72 | 0.110 |
Why?
|
Transcription, Genetic | 1 | 2020 | 1708 | 0.110 |
Why?
|
Papio | 4 | 2021 | 57 | 0.110 |
Why?
|
Cough | 1 | 2015 | 94 | 0.110 |
Why?
|
Anti-Bacterial Agents | 2 | 2016 | 2371 | 0.110 |
Why?
|
Nasopharyngitis | 1 | 2013 | 5 | 0.110 |
Why?
|
Proteobacteria | 1 | 2013 | 19 | 0.110 |
Why?
|
Patient Discharge | 2 | 2015 | 492 | 0.110 |
Why?
|
Case-Control Studies | 5 | 2023 | 3310 | 0.110 |
Why?
|
Gene Expression Profiling | 3 | 2018 | 1757 | 0.110 |
Why?
|
Apnea | 1 | 2013 | 31 | 0.110 |
Why?
|
Follow-Up Studies | 6 | 2019 | 5169 | 0.110 |
Why?
|
Predictive Value of Tests | 2 | 2020 | 2182 | 0.110 |
Why?
|
Mass Vaccination | 1 | 2013 | 12 | 0.100 |
Why?
|
Polysaccharides | 1 | 2014 | 138 | 0.100 |
Why?
|
Epitopes, T-Lymphocyte | 2 | 2023 | 125 | 0.100 |
Why?
|
Vaccines, Virosome | 1 | 2012 | 1 | 0.100 |
Why?
|
Sf9 Cells | 1 | 2012 | 9 | 0.100 |
Why?
|
Sequence Alignment | 1 | 2014 | 620 | 0.100 |
Why?
|
Technology, Pharmaceutical | 1 | 2012 | 20 | 0.100 |
Why?
|
Vaccines | 1 | 2017 | 366 | 0.100 |
Why?
|
Mutation | 2 | 2024 | 5906 | 0.100 |
Why?
|
Biotechnology | 1 | 2012 | 56 | 0.100 |
Why?
|
Odds Ratio | 4 | 2016 | 1253 | 0.100 |
Why?
|
Adrenal Cortex Hormones | 1 | 2014 | 319 | 0.100 |
Why?
|
Pneumonia, Bacterial | 1 | 2013 | 77 | 0.100 |
Why?
|
Immunization | 5 | 1997 | 308 | 0.100 |
Why?
|
Immunoglobulins | 2 | 1990 | 173 | 0.100 |
Why?
|
Single-Blind Method | 1 | 2012 | 240 | 0.100 |
Why?
|
Gastrointestinal Diseases | 3 | 2014 | 339 | 0.100 |
Why?
|
Cathelicidins | 3 | 2017 | 13 | 0.090 |
Why?
|
Picornaviridae | 1 | 2011 | 20 | 0.090 |
Why?
|
Sensitivity and Specificity | 4 | 2021 | 2055 | 0.090 |
Why?
|
Pregnancy Trimester, Third | 3 | 2020 | 120 | 0.090 |
Why?
|
Disease Susceptibility | 3 | 2024 | 300 | 0.090 |
Why?
|
Cattle | 2 | 2024 | 567 | 0.090 |
Why?
|
Vaccines, Subunit | 2 | 2021 | 66 | 0.090 |
Why?
|
Surveys and Questionnaires | 2 | 2018 | 3675 | 0.090 |
Why?
|
Orthomyxoviridae Infections | 2 | 2024 | 59 | 0.090 |
Why?
|
MicroRNAs | 1 | 2018 | 858 | 0.090 |
Why?
|
Molecular Sequence Data | 2 | 2014 | 3898 | 0.090 |
Why?
|
Clinical Laboratory Techniques | 1 | 2012 | 139 | 0.090 |
Why?
|
Cluster Analysis | 3 | 2017 | 402 | 0.090 |
Why?
|
Cross Reactions | 3 | 2004 | 192 | 0.090 |
Why?
|
Otitis Media | 2 | 2009 | 85 | 0.090 |
Why?
|
Serotyping | 2 | 2008 | 178 | 0.080 |
Why?
|
School Health Services | 1 | 2010 | 99 | 0.080 |
Why?
|
Immunization, Passive | 1 | 1990 | 120 | 0.080 |
Why?
|
Mice | 12 | 2025 | 17740 | 0.080 |
Why?
|
Age Distribution | 1 | 2010 | 418 | 0.080 |
Why?
|
Klebsiella | 1 | 1989 | 9 | 0.080 |
Why?
|
Antibody Affinity | 2 | 2020 | 39 | 0.080 |
Why?
|
Arvicolinae | 1 | 1989 | 4 | 0.080 |
Why?
|
Premature Birth | 1 | 2013 | 388 | 0.080 |
Why?
|
Malabsorption Syndromes | 1 | 1989 | 36 | 0.080 |
Why?
|
Culture Techniques | 2 | 2004 | 86 | 0.080 |
Why?
|
Short Bowel Syndrome | 1 | 1989 | 66 | 0.080 |
Why?
|
Reproducibility of Results | 4 | 2019 | 2878 | 0.080 |
Why?
|
Practice Patterns, Physicians' | 1 | 2014 | 729 | 0.070 |
Why?
|
DNA Primers | 3 | 2019 | 657 | 0.070 |
Why?
|
Macaca fascicularis | 2 | 2020 | 87 | 0.070 |
Why?
|
Schools, Nursery | 1 | 2007 | 3 | 0.070 |
Why?
|
Catheterization, Central Venous | 1 | 1989 | 128 | 0.070 |
Why?
|
Regression Analysis | 2 | 2020 | 776 | 0.070 |
Why?
|
Immunogenicity, Vaccine | 2 | 2020 | 106 | 0.070 |
Why?
|
Genetic Therapy | 3 | 2002 | 688 | 0.070 |
Why?
|
Microbial Sensitivity Tests | 2 | 2015 | 791 | 0.070 |
Why?
|
Intensive Care Units, Neonatal | 2 | 2005 | 316 | 0.070 |
Why?
|
Lipid Metabolism | 2 | 2020 | 356 | 0.070 |
Why?
|
Chemokines | 1 | 2007 | 134 | 0.070 |
Why?
|
Epithelial Cells | 2 | 2024 | 909 | 0.060 |
Why?
|
Morbidity | 1 | 2007 | 248 | 0.060 |
Why?
|
Liver | 4 | 2002 | 1748 | 0.060 |
Why?
|
Indazoles | 2 | 2015 | 25 | 0.060 |
Why?
|
Metabolomics | 2 | 2020 | 422 | 0.060 |
Why?
|
Aerosols | 3 | 2002 | 65 | 0.060 |
Why?
|
Michigan | 1 | 2005 | 42 | 0.060 |
Why?
|
Health Services | 1 | 2005 | 70 | 0.060 |
Why?
|
Pseudomonas Infections | 1 | 1986 | 114 | 0.060 |
Why?
|
Livestock | 1 | 2024 | 12 | 0.060 |
Why?
|
Farmers | 1 | 2024 | 12 | 0.060 |
Why?
|
Sepsis | 1 | 1989 | 483 | 0.060 |
Why?
|
Epitopes | 2 | 2018 | 433 | 0.060 |
Why?
|
Office Visits | 1 | 2005 | 76 | 0.060 |
Why?
|
Influenza in Birds | 1 | 2024 | 27 | 0.060 |
Why?
|
Consumer Product Safety | 1 | 2004 | 32 | 0.060 |
Why?
|
Birds | 1 | 2024 | 85 | 0.060 |
Why?
|
Epoxy Compounds | 1 | 2024 | 18 | 0.050 |
Why?
|
Mutation Rate | 1 | 2024 | 67 | 0.050 |
Why?
|
Registries | 1 | 2010 | 1434 | 0.050 |
Why?
|
DNA, Bacterial | 2 | 2018 | 473 | 0.050 |
Why?
|
Gene Expression | 2 | 2021 | 1554 | 0.050 |
Why?
|
Rotavirus Infections | 1 | 2007 | 354 | 0.050 |
Why?
|
Escherichia coli | 1 | 1989 | 968 | 0.050 |
Why?
|
Restriction Mapping | 1 | 2003 | 190 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 2 | 2021 | 3175 | 0.050 |
Why?
|
Rotavirus | 1 | 2007 | 497 | 0.050 |
Why?
|
Capsid Proteins | 1 | 2004 | 184 | 0.050 |
Why?
|
Cell Line, Tumor | 2 | 2016 | 3422 | 0.050 |
Why?
|
Apoptosis | 1 | 2010 | 1819 | 0.050 |
Why?
|
Oxazines | 1 | 2023 | 25 | 0.050 |
Why?
|
Disease Progression | 2 | 2019 | 2084 | 0.050 |
Why?
|
Injections, Subcutaneous | 1 | 2003 | 130 | 0.050 |
Why?
|
Crystallography, X-Ray | 1 | 2024 | 358 | 0.050 |
Why?
|
Heparin | 1 | 2004 | 217 | 0.050 |
Why?
|
Statistics as Topic | 2 | 2014 | 256 | 0.050 |
Why?
|
Multiplex Polymerase Chain Reaction | 1 | 2022 | 29 | 0.050 |
Why?
|
A549 Cells | 1 | 2022 | 44 | 0.050 |
Why?
|
Genetic Engineering | 1 | 2003 | 161 | 0.050 |
Why?
|
Sequence Analysis | 1 | 2021 | 54 | 0.050 |
Why?
|
Vaccines, Combined | 2 | 1995 | 39 | 0.050 |
Why?
|
Neuraminidase | 1 | 2022 | 36 | 0.050 |
Why?
|
Turbinates | 1 | 2021 | 12 | 0.050 |
Why?
|
Peripartum Period | 1 | 2022 | 28 | 0.050 |
Why?
|
Blotting, Western | 3 | 2003 | 1111 | 0.050 |
Why?
|
Immune Evasion | 1 | 2021 | 35 | 0.050 |
Why?
|
Sequence Analysis, RNA | 1 | 2024 | 372 | 0.050 |
Why?
|
Immune System | 1 | 2002 | 90 | 0.050 |
Why?
|
Vomiting | 1 | 2002 | 103 | 0.050 |
Why?
|
Pyridines | 1 | 2023 | 235 | 0.050 |
Why?
|
DNA, Viral | 2 | 2013 | 478 | 0.050 |
Why?
|
Cytotoxicity Tests, Immunologic | 1 | 2001 | 23 | 0.050 |
Why?
|
Species Specificity | 1 | 2022 | 551 | 0.040 |
Why?
|
Diagnosis, Differential | 3 | 2016 | 1893 | 0.040 |
Why?
|
Open Reading Frames | 1 | 2021 | 212 | 0.040 |
Why?
|
Gene Transfer Techniques | 2 | 1999 | 358 | 0.040 |
Why?
|
Cost-Benefit Analysis | 2 | 2017 | 511 | 0.040 |
Why?
|
Molecular Epidemiology | 1 | 2021 | 155 | 0.040 |
Why?
|
Saponins | 1 | 2020 | 22 | 0.040 |
Why?
|
Immune Sera | 1 | 2020 | 95 | 0.040 |
Why?
|
Hospitals, Pediatric | 2 | 2016 | 768 | 0.040 |
Why?
|
Pregnant Women | 1 | 2022 | 143 | 0.040 |
Why?
|
Evolution, Molecular | 1 | 2024 | 668 | 0.040 |
Why?
|
Public Health | 1 | 2023 | 267 | 0.040 |
Why?
|
Neutrophils | 2 | 2017 | 381 | 0.040 |
Why?
|
DNA, Complementary | 1 | 2021 | 463 | 0.040 |
Why?
|
Tablets | 1 | 2020 | 28 | 0.040 |
Why?
|
Forecasting | 1 | 2002 | 352 | 0.040 |
Why?
|
Disease Management | 2 | 2014 | 528 | 0.040 |
Why?
|
Poisson Distribution | 1 | 2020 | 51 | 0.040 |
Why?
|
Nebulizers and Vaporizers | 1 | 2020 | 57 | 0.040 |
Why?
|
Nitric Oxide Synthase | 1 | 2001 | 176 | 0.040 |
Why?
|
Decision Trees | 1 | 2020 | 50 | 0.040 |
Why?
|
Cold Temperature | 4 | 2004 | 78 | 0.040 |
Why?
|
Immunoglobulin Idiotypes | 1 | 2020 | 11 | 0.040 |
Why?
|
Endemic Diseases | 1 | 2020 | 57 | 0.040 |
Why?
|
Sphingolipids | 1 | 2020 | 28 | 0.040 |
Why?
|
Positive-Pressure Respiration | 1 | 2020 | 84 | 0.040 |
Why?
|
Carnitine | 1 | 2020 | 74 | 0.040 |
Why?
|
Adenosine Monophosphate | 1 | 2020 | 42 | 0.040 |
Why?
|
Half-Life | 1 | 2020 | 156 | 0.040 |
Why?
|
Gene Frequency | 1 | 2021 | 728 | 0.040 |
Why?
|
Th1 Cells | 1 | 2020 | 153 | 0.040 |
Why?
|
Cytidine Deaminase | 1 | 1999 | 31 | 0.040 |
Why?
|
Abdominal Pain | 1 | 2002 | 306 | 0.040 |
Why?
|
Public Health Surveillance | 1 | 2019 | 38 | 0.040 |
Why?
|
Program Development | 1 | 2000 | 182 | 0.040 |
Why?
|
Patient Selection | 1 | 2003 | 694 | 0.040 |
Why?
|
RNA Stability | 1 | 2020 | 84 | 0.040 |
Why?
|
DNA Probes | 1 | 2019 | 124 | 0.040 |
Why?
|
Limit of Detection | 1 | 2019 | 62 | 0.040 |
Why?
|
Alanine | 1 | 2020 | 187 | 0.040 |
Why?
|
Belgium | 1 | 2019 | 43 | 0.040 |
Why?
|
Healthy Volunteers | 1 | 2019 | 134 | 0.040 |
Why?
|
Hypercholesterolemia | 1 | 2001 | 225 | 0.040 |
Why?
|
Tumor Cells, Cultured | 1 | 2001 | 1078 | 0.040 |
Why?
|
Developed Countries | 1 | 2019 | 36 | 0.040 |
Why?
|
Oxygen | 1 | 2022 | 556 | 0.040 |
Why?
|
Endothelium, Vascular | 1 | 2002 | 489 | 0.040 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2017 | 682 | 0.040 |
Why?
|
Immunocompetence | 1 | 1998 | 33 | 0.040 |
Why?
|
Alum Compounds | 2 | 1989 | 41 | 0.040 |
Why?
|
Parturition | 1 | 2019 | 63 | 0.040 |
Why?
|
Hypoxia | 1 | 2020 | 249 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2019 | 273 | 0.040 |
Why?
|
Income | 1 | 2019 | 132 | 0.040 |
Why?
|
Respiratory Function Tests | 1 | 1999 | 198 | 0.040 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2005 | 604 | 0.040 |
Why?
|
Program Evaluation | 1 | 2000 | 440 | 0.040 |
Why?
|
HIV | 1 | 2019 | 181 | 0.040 |
Why?
|
World Health Organization | 1 | 2018 | 107 | 0.040 |
Why?
|
DNA, Ribosomal | 1 | 2018 | 52 | 0.040 |
Why?
|
Corynebacterium | 1 | 2017 | 9 | 0.040 |
Why?
|
Granzymes | 1 | 2017 | 37 | 0.040 |
Why?
|
Haemophilus influenzae | 1 | 2018 | 130 | 0.040 |
Why?
|
Genotyping Techniques | 1 | 2017 | 105 | 0.040 |
Why?
|
Bronchoalveolar Lavage Fluid | 4 | 2008 | 149 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2002 | 1095 | 0.030 |
Why?
|
Immunodominant Epitopes | 1 | 2017 | 50 | 0.030 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 69 | 0.030 |
Why?
|
Metabolic Networks and Pathways | 1 | 2018 | 187 | 0.030 |
Why?
|
Drug Stability | 1 | 2016 | 58 | 0.030 |
Why?
|
Prevotella | 1 | 2016 | 8 | 0.030 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 260 | 0.030 |
Why?
|
Reverse Genetics | 1 | 2016 | 15 | 0.030 |
Why?
|
Protein Engineering | 1 | 2016 | 72 | 0.030 |
Why?
|
Child, Hospitalized | 1 | 2017 | 74 | 0.030 |
Why?
|
Cholesterol | 1 | 1999 | 540 | 0.030 |
Why?
|
Genetic Drift | 1 | 2016 | 22 | 0.030 |
Why?
|
Patient Outcome Assessment | 1 | 2017 | 92 | 0.030 |
Why?
|
Pre-Exposure Prophylaxis | 1 | 2016 | 36 | 0.030 |
Why?
|
Prenatal Care | 1 | 2019 | 348 | 0.030 |
Why?
|
Bone Marrow Transplantation | 2 | 1996 | 564 | 0.030 |
Why?
|
Urinalysis | 1 | 1996 | 52 | 0.030 |
Why?
|
Temperature | 1 | 2016 | 307 | 0.030 |
Why?
|
Hematuria | 1 | 1996 | 54 | 0.030 |
Why?
|
Cell Fusion | 1 | 2015 | 37 | 0.030 |
Why?
|
Opportunistic Infections | 1 | 1996 | 78 | 0.030 |
Why?
|
Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2016 | 59 | 0.030 |
Why?
|
Animals, Newborn | 1 | 1999 | 1019 | 0.030 |
Why?
|
Pichia | 1 | 2015 | 56 | 0.030 |
Why?
|
Socioeconomic Factors | 2 | 2014 | 858 | 0.030 |
Why?
|
Safety-Based Drug Withdrawals | 1 | 2015 | 1 | 0.030 |
Why?
|
Nasal Decongestants | 1 | 2015 | 4 | 0.030 |
Why?
|
Mothers | 2 | 2015 | 356 | 0.030 |
Why?
|
Streptococcus pneumoniae | 1 | 2018 | 376 | 0.030 |
Why?
|
Antitussive Agents | 1 | 2015 | 3 | 0.030 |
Why?
|
Inflammation Mediators | 1 | 2017 | 246 | 0.030 |
Why?
|
Expectorants | 1 | 2015 | 8 | 0.030 |
Why?
|
Intubation | 1 | 2015 | 17 | 0.030 |
Why?
|
Bronchi | 1 | 2015 | 99 | 0.030 |
Why?
|
Clinical Protocols | 1 | 2016 | 240 | 0.030 |
Why?
|
Heart Defects, Congenital | 1 | 2007 | 1833 | 0.030 |
Why?
|
Tachypnea | 1 | 2015 | 1 | 0.030 |
Why?
|
High-Frequency Ventilation | 1 | 2015 | 17 | 0.030 |
Why?
|
Cross Protection | 1 | 2014 | 7 | 0.030 |
Why?
|
Multilevel Analysis | 1 | 2014 | 8 | 0.030 |
Why?
|
Leukocyte Reduction Procedures | 1 | 2014 | 3 | 0.030 |
Why?
|
Environment | 1 | 1996 | 142 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2015 | 1685 | 0.030 |
Why?
|
Specimen Handling | 1 | 2015 | 142 | 0.030 |
Why?
|
Transcriptome | 1 | 2021 | 978 | 0.030 |
Why?
|
Blood Cell Count | 1 | 2014 | 69 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2017 | 760 | 0.030 |
Why?
|
Macrophages, Alveolar | 1 | 2014 | 49 | 0.030 |
Why?
|
Child Nutritional Physiological Phenomena | 1 | 1996 | 174 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2015 | 150 | 0.030 |
Why?
|
Receptors, Fc | 1 | 2014 | 29 | 0.030 |
Why?
|
Complement C1q | 1 | 2014 | 19 | 0.030 |
Why?
|
Contig Mapping | 1 | 2014 | 55 | 0.030 |
Why?
|
Cells, Cultured | 3 | 2004 | 3044 | 0.030 |
Why?
|
Molecular Structure | 1 | 2015 | 294 | 0.030 |
Why?
|
Radiography, Thoracic | 1 | 2014 | 150 | 0.030 |
Why?
|
Dogs | 1 | 2015 | 772 | 0.030 |
Why?
|
Patient Transfer | 1 | 2015 | 108 | 0.030 |
Why?
|
Structure-Activity Relationship | 1 | 2015 | 581 | 0.030 |
Why?
|
Adoptive Transfer | 1 | 2014 | 235 | 0.030 |
Why?
|
RNA, Messenger | 1 | 2020 | 2814 | 0.030 |
Why?
|
Signal Transduction | 2 | 2018 | 4597 | 0.030 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2008 | 471 | 0.030 |
Why?
|
Catheterization, Peripheral | 1 | 2014 | 121 | 0.030 |
Why?
|
Sputum | 1 | 2013 | 106 | 0.030 |
Why?
|
Ambulatory Care | 1 | 2015 | 390 | 0.020 |
Why?
|
Immunotherapy | 1 | 2017 | 678 | 0.020 |
Why?
|
Models, Molecular | 1 | 2015 | 1084 | 0.020 |
Why?
|
Protein Structure, Tertiary | 1 | 2014 | 768 | 0.020 |
Why?
|
Radiography | 1 | 2014 | 802 | 0.020 |
Why?
|
Virus Cultivation | 1 | 2011 | 76 | 0.020 |
Why?
|
Serologic Tests | 1 | 2011 | 118 | 0.020 |
Why?
|
Vitamin D | 1 | 2012 | 166 | 0.020 |
Why?
|
Intensive Care Units, Pediatric | 1 | 2015 | 479 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2016 | 887 | 0.020 |
Why?
|
Ribonucleosides | 1 | 1990 | 15 | 0.020 |
Why?
|
Emergency Medicine | 1 | 2012 | 151 | 0.020 |
Why?
|
Down-Regulation | 1 | 2013 | 692 | 0.020 |
Why?
|
Drug Evaluation | 1 | 1990 | 105 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2013 | 365 | 0.020 |
Why?
|
Injections, Intravenous | 1 | 1990 | 248 | 0.020 |
Why?
|
Up-Regulation | 1 | 2013 | 874 | 0.020 |
Why?
|
Protein Binding | 1 | 2014 | 1756 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2013 | 1033 | 0.020 |
Why?
|
Emergency Service, Hospital | 1 | 2017 | 1071 | 0.020 |
Why?
|
Colony Count, Microbial | 1 | 1989 | 85 | 0.020 |
Why?
|
Chemical Precipitation | 1 | 1989 | 15 | 0.020 |
Why?
|
Herpesviridae Infections | 1 | 1990 | 142 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2018 | 2527 | 0.020 |
Why?
|
Cytopathogenic Effect, Viral | 1 | 2008 | 29 | 0.020 |
Why?
|
Mice, Inbred C57BL | 3 | 2002 | 4417 | 0.020 |
Why?
|
Catheters, Indwelling | 1 | 1989 | 138 | 0.020 |
Why?
|
Hemagglutination Inhibition Tests | 2 | 2000 | 113 | 0.020 |
Why?
|
Antigens | 1 | 1988 | 156 | 0.020 |
Why?
|
Ovalbumin | 1 | 1988 | 319 | 0.020 |
Why?
|
Pollen | 1 | 1988 | 46 | 0.020 |
Why?
|
HT29 Cells | 1 | 2007 | 44 | 0.020 |
Why?
|
Diarrhea, Infantile | 1 | 2007 | 35 | 0.020 |
Why?
|
Quality of Life | 1 | 2016 | 1906 | 0.020 |
Why?
|
Immunoassay | 1 | 2007 | 131 | 0.020 |
Why?
|
Pseudomonas Vaccines | 1 | 1986 | 1 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2014 | 1538 | 0.020 |
Why?
|
Mucus | 1 | 1986 | 36 | 0.020 |
Why?
|
Comorbidity | 2 | 2004 | 1526 | 0.020 |
Why?
|
Mucous Membrane | 1 | 1986 | 89 | 0.020 |
Why?
|
Bacterial Vaccines | 1 | 1986 | 99 | 0.020 |
Why?
|
Hypersensitivity | 1 | 1988 | 185 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 1990 | 1114 | 0.020 |
Why?
|
Pulmonary Alveoli | 1 | 1986 | 134 | 0.020 |
Why?
|
Phagocytosis | 1 | 1986 | 171 | 0.020 |
Why?
|
Inflammatory Bowel Diseases | 1 | 1989 | 303 | 0.010 |
Why?
|
Pseudomonas aeruginosa | 1 | 1986 | 162 | 0.010 |
Why?
|
HLA-A Antigens | 1 | 2004 | 35 | 0.010 |
Why?
|
Weight Loss | 1 | 2008 | 481 | 0.010 |
Why?
|
Epitope Mapping | 1 | 2004 | 80 | 0.010 |
Why?
|
Gastroenteritis | 1 | 2007 | 348 | 0.010 |
Why?
|
Conserved Sequence | 1 | 2004 | 290 | 0.010 |
Why?
|
Drug Therapy, Combination | 2 | 1997 | 1158 | 0.010 |
Why?
|
Immunologic Memory | 1 | 2003 | 190 | 0.010 |
Why?
|
Macrophages | 1 | 1986 | 626 | 0.010 |
Why?
|
In Vitro Techniques | 1 | 2003 | 971 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2007 | 615 | 0.010 |
Why?
|
beta-Galactosidase | 1 | 2002 | 147 | 0.010 |
Why?
|
Platelet Count | 1 | 2002 | 137 | 0.010 |
Why?
|
Life Expectancy | 1 | 2001 | 53 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 2002 | 396 | 0.010 |
Why?
|
Korea | 1 | 2001 | 35 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2002 | 391 | 0.010 |
Why?
|
Enzyme Induction | 1 | 2001 | 104 | 0.010 |
Why?
|
Apolipoproteins E | 1 | 2001 | 192 | 0.010 |
Why?
|
Carcinoma, Small Cell | 1 | 2001 | 51 | 0.010 |
Why?
|
Interleukin-8 | 1 | 2002 | 210 | 0.010 |
Why?
|
Dendritic Cells | 1 | 2003 | 414 | 0.010 |
Why?
|
Milk, Human | 1 | 2003 | 300 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2002 | 552 | 0.010 |
Why?
|
Virulence | 1 | 2001 | 265 | 0.010 |
Why?
|
Thrombocytopenia | 1 | 2002 | 225 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2002 | 420 | 0.010 |
Why?
|
APOBEC-1 Deaminase | 1 | 1999 | 12 | 0.010 |
Why?
|
North America | 1 | 2000 | 243 | 0.010 |
Why?
|
Alleles | 1 | 2004 | 1615 | 0.010 |
Why?
|
Helper Viruses | 1 | 1999 | 45 | 0.010 |
Why?
|
Dexamethasone | 1 | 2001 | 270 | 0.010 |
Why?
|
Spleen | 1 | 1999 | 281 | 0.010 |
Why?
|
Macaca mulatta | 1 | 2000 | 489 | 0.010 |
Why?
|
Rabbits | 1 | 1999 | 718 | 0.010 |
Why?
|
Culture Media | 1 | 1998 | 181 | 0.010 |
Why?
|
Cell Division | 1 | 1999 | 780 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2001 | 1704 | 0.010 |
Why?
|
Base Sequence | 1 | 2001 | 3109 | 0.010 |
Why?
|
Anticholesteremic Agents | 1 | 1999 | 235 | 0.010 |
Why?
|
Gambia | 1 | 1996 | 28 | 0.010 |
Why?
|
Virology | 1 | 1996 | 31 | 0.010 |
Why?
|
Binding, Competitive | 1 | 1996 | 192 | 0.010 |
Why?
|
Steroids | 1 | 1997 | 202 | 0.010 |
Why?
|
Air Microbiology | 1 | 1994 | 10 | 0.010 |
Why?
|
Adaptation, Physiological | 1 | 1996 | 268 | 0.010 |
Why?
|
Neoplasms | 1 | 1989 | 2794 | 0.010 |
Why?
|
Anti-Inflammatory Agents | 1 | 1997 | 292 | 0.010 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 1996 | 243 | 0.010 |
Why?
|
Oxygen Inhalation Therapy | 1 | 1994 | 92 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2001 | 3756 | 0.010 |
Why?
|
Leukemia | 1 | 1996 | 367 | 0.010 |
Why?
|
Aging | 1 | 1999 | 1181 | 0.010 |
Why?
|
Survival Analysis | 1 | 1995 | 1496 | 0.010 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 1990 | 343 | 0.010 |
Why?
|
Aluminum | 1 | 1988 | 12 | 0.000 |
Why?
|
Sulfates | 1 | 1988 | 35 | 0.000 |
Why?
|